{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "End of Study Visit Window",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_2",
        "name": "Enrollment",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_3",
        "name": "CRU Admission 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -8,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_4",
        "name": "CRU Discharge 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 9,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_5",
        "name": "CRU Re-admission",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 22,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 1
      },
      {
        "id": "timing_6",
        "name": "Zinc Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose",
        "windowLower": -21,
        "windowUpper": -1
      },
      {
        "id": "timing_7",
        "name": "Tetrathiomolybdate Washout",
        "type": "Within",
        "unit": "years",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose",
        "windowLower": -365,
        "windowUpper": -1
      },
      {
        "id": "timing_8",
        "name": "Experimental Therapy Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening",
        "windowLower": -90,
        "windowUpper": -1
      },
      {
        "id": "timing_9",
        "name": "Prescription Medication Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14,
        "windowLower": -14,
        "windowUpper": -1
      },
      {
        "id": "timing_10",
        "name": "Non-Prescription Medication Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7,
        "windowLower": -7,
        "windowUpper": -1
      },
      {
        "id": "timing_11",
        "name": "Alcohol Consumption Washout",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 48,
        "relativeTo": "First Dose",
        "windowLower": -48,
        "windowUpper": -1
      },
      {
        "id": "timing_12",
        "name": "Recurring Pregnancy Test",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_13",
        "name": "Chelator Therapy Washout",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose",
        "windowLower": -4,
        "windowUpper": -1
      },
      {
        "id": "timing_14",
        "name": "Outpatient Dosing Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 0,
        "windowLower": -1,
        "windowUpper": 1
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Dose Titration Safety Review",
        "instanceType": "Condition",
        "description": "Safety data must be reviewed by the Safety Review Committee before dose titration.",
        "text": "Before titration to 30 mg/day, the Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_2",
        "name": "Outpatient Period Extension",
        "instanceType": "Condition",
        "description": "The outpatient period can be extended with Investigator approval.",
        "text": "The Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
      },
      {
        "id": "cond_3",
        "name": "ALT or AST Elevation (Moderate)",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction due to moderate liver enzyme elevation.",
        "text": "ALT or AST > 3 × ULN and ≤ 5 × ULN"
      },
      {
        "id": "cond_4",
        "name": "ALT or AST Elevation (High)",
        "instanceType": "Condition",
        "description": "Criteria for dose interruption due to high liver enzyme elevation.",
        "text": "ALT or AST > 5 × ULN"
      },
      {
        "id": "cond_5",
        "name": "Hemoglobin Decrease",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction due to a significant decrease in hemoglobin.",
        "text": "Hemoglobin > 2 g/dL ↓ from baseline"
      },
      {
        "id": "cond_6",
        "name": "Platelet Decrease",
        "instanceType": "Condition",
        "description": "Criteria for dose reduction due to a significant decrease in platelets.",
        "text": "Platelets > 30% ↓ from baseline"
      },
      {
        "id": "cond_7",
        "name": "Bilirubin Elevation with ALT Elevation",
        "instanceType": "Condition",
        "description": "Criteria for dose interruption due to concurrent bilirubin and ALT elevation.",
        "text": "Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN, indicative of liver injury"
      },
      {
        "id": "cond_8",
        "name": "Neurological Worsening",
        "instanceType": "Condition",
        "description": "Criteria for evaluating dose modification due to neurological worsening.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_9",
        "name": "Dosing Fasting Requirement",
        "instanceType": "Condition",
        "description": "Condition for administering study intervention.",
        "text": "study intervention will be administered after an overnight fast (ie, at least 10 hours)"
      },
      {
        "id": "cond_10",
        "name": "Post-Dose Meal Delay",
        "instanceType": "Condition",
        "description": "Condition for meals after study intervention administration.",
        "text": "meals should be delayed a minimum of 2 hours after dosing"
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Titration to 30mg",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "dose_15mg",
        "toElementId": "dose_30mg",
        "text": "Following the Run-in Period, participants will be administered ALXN1840 at 15 mg/day for a treatment period of approximately 28 days followed by titration up to 30 mg/day on Day 29."
      },
      {
        "id": "trans_2",
        "name": "Dose Reduction for ALT/AST",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT or AST > 3 × ULN and ≤ 5 × ULN, reduce dose to previous dose level."
      },
      {
        "id": "trans_3",
        "name": "Dose Interruption for ALT/AST",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT or AST > 5 × ULN, temporary interruption of dosing."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Hematology",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Hemoglobin > 2 g/dL ↓ from baseline OR Platelets > 30% ↓ from baseline, reduce dose to previous dose level."
      },
      {
        "id": "trans_5",
        "name": "Dose Interruption for Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2 × ULN Accompanied by ALT > 3 × ULN, temporary interruption of dosing."
      },
      {
        "id": "trans_6",
        "name": "Dose Modification for Neurological Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on copper control parameters and relevant clinical data."
      },
      {
        "id": "trans_7",
        "name": "Discontinuation for Hypersensitivity",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if a serious hypersensitivity reaction occurs."
      },
      {
        "id": "trans_8",
        "name": "Discontinuation for Infection",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if a severe uncontrolled infection occurs."
      },
      {
        "id": "trans_9",
        "name": "Discontinuation for Pregnancy",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for pregnancy or planned pregnancy."
      },
      {
        "id": "trans_10",
        "name": "Post-Study Therapy Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_treatment",
        "toElementId": "epoch_followup",
        "text": "Following completion of both inpatient periods of the study (ie, Day 40), participants will transition to therapy that was discontinued before enrollment, or transition to other standard of care therapy."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities (SoA)."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretionary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Sponsor Termination",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to close the study site or terminate the study at any time for any reason at the sole discretion of Alexion."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "Day 23",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for titrating dose from 15 mg/day to 30 mg/day based on safety review through Day 23.",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_2",
        "name": "Ongoing Dose Modification Decision",
        "timepointId": "any_safety_assessment",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Event-driven decision point to modify, interrupt, or discontinue dose based on safety parameters (liver function, hematology, neurological status).",
        "conditionIds": [
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6",
          "cond_7",
          "cond_8"
        ]
      }
    ],
    "summary": {
      "timingCount": 14,
      "conditionCount": 10,
      "transitionRuleCount": 10,
      "exitCount": 5
    }
  }
}